Cases
Representative Matters: Aspex Eyewear Inc. v. Zenni Optical, LLC, 0: 09-cv-61468 (S.D. Fla.). Obtained summary judgment decision barring patent infringement claims on grounds of collateral estoppel in litigation related to magnetically attached sunglass frames for eyeglasses.
Defended leading enterprise software company
its decision support software against infringement claims based on four patents relating to object-oriented programming
relational database technology.
Represented Amici Curiae, including Hewlett-Packard, Abbyy USA Software House
Netapp, in support of a petition for a writ of certiorari from the U.S. Supreme Court.
Conducted prior art review
developed invalidity positions for Inter Partes Review request filed against patents owned by non-practicing entity, Zond, Inc.
Outside the Box Innovations, LLC, et al. v. Travel Caddy, Inc., et al. (Fed. Cir.). Federal Circuit upheld a lower court ruling that client's carrying cases for tools did not infringe appellant's patents.
General Mills, Inc. v. Hom/Ade Food Sales, Inc., 2: 06-cv-00003-TJW (E.D. Tex.). Represented defendant against claims that it infringed a General Mills patent directed to frozen biscuits. Case settled shortly before Markman hearing.
Intelligent Designs 2000 Corp. v. Sprint/United Management Co., et al., 11-cv-00437 (D. Colo.). Represented Home Depot in patent infringement litigation related to cell phone holders. Case settled.
S
ow Media, LLC v. Fix Medical Spa, LLC, 2: 11-cv-00854-RSM (W.D. Wash.). Represented beauty product retailer
magazine publisher in an action for infringement of the NEWBEAUTY trademark
trade dress infringement brought against a beauty salon
medical spa. Case settled.
S
ow Media, LLC v. Renew Beauty Med Spa, Inc., 3: 11-cv-02082-G (N.D. Texas). Represented beauty product retailer
magazine publisher in an action for infringement of the NEWBEAUTY trademark
trade dress infringement brought against a beauty salon
medical spa. Case settled.
Represented Quest Diagnostic in the sale of a stream of royalty revenue from commercialization of the drug c
idate Ibrutinib to Royal Pharma for $485 million in cash.
Represented various companies in asset purchase agreements involving the purchase or sale of intellectual property assets.
Represented numerous nonprofit organizations in their efforts to obtain trademark registrations, as well as protect
defend their rights against third-parties.
